Events

Careers with impact: working in ML applied drug discovery

One of the unexpected outcomes of the COVID-19 pandemic has been that it has made technology talent aware of the opportunities to use technology to tackle some of the world’s most important and pressing healthcare challenges. 


4th November 2020 | 5.30pm UK time - 12:30pm NYC Time

While interest in joining the industry has increased, many are prevented from taking the leap due to a belief that they do not possess the necessary scientific knowledge. This invisible door is preventing talented people from entering the industry. Worryingly, this problem could be amplified for women in tech, who are already less likely to apply for a role they’re not 100% qualified for.

This meetup will look to demystify AI in drug discovery in order to empower female tech talent to take the leap into this important growth industry. We will counter preconceptions that only those with scientific knowledge can join, by showcasing how we work at BenevolentAI, where we bring together cross-functional teams of machine learning engineers, AI scientists, data scientists and informaticians to co-create our AI platform for drug discovery, alongside our seasoned drug discoverers.

This is a free event and we’d love you to join us for an evening of open dialogue and ideas exchange. 

→ Register here

Event agenda

17:30 – Grab a drink of your choice, get comfy and logon for an intro from Sam

17:35 – 19:55 – Panel discussion part I: countering preconceptions that only those with scientific knowledge can join the drug discovery industry

17:55 - 18:15 – Panel discussion part II: exploring the importance of diverse skills and experiences in AI applied drug discovery, and discussing practical actions to building diverse and inclusive teams.

18:15 - 18:20 – Q&As

18:20 - 18:50 – Split into virtual rooms for networking and a Q&A opportunity with the Benevolent team.


Speakers:

Ana Leite | Lead Bioinformatic Data Scientist

Aylin Cakiroglu | Senior AI Scientist

Paidi Creed | Director, AI Science

Saee Paliwal | Lead AI Scientist

Sam Coulter (Moderator) | Talent Acquisition Specialist


More Posts

You Might Also Like

News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022